Close
  • SMC open account icon Open an A/C
    • Open an A/C
    • CHOOSE YOUR OPTION(S)
    • Trading A/c
    • Mutual Fund A/c
    • NBFC A/c
    • NPS A/c
  • SENSEX May 08 2024 12:00
    73,466.39 -45.46 (-0.06%)
  • NIFTY May 08 2024 12:00
    22,302.50 0.00 (0.00%)
  • SENSEX May 08 2024 12:00
    73,466.39 -45.46 (-0.06%)
  • NIFTY May 08 2024 12:00
    22,302.50 0.00 (0.00%)
  • Nasdaq May 08 2024 04:30
    16,332.56 -16.69 (-0.10%)
  • DJIA May 08 2024 04:30
    38,884.26 +31.99 ( +0.08%)
  • S&P 500 May 08 2024 04:30
    5,187.70 +6.96 ( +0.13%)
  • Hang Seng May 08 2024 02:10
    18,313.86 -165.51 (-0.90%)
  • Crude Oil May 08 2024 06:56
    6,501.00 -84.00 (-1.28%)
  • Gold May 08 2024 06:56
    71,056.00 -92.00 (-0.13%)
  • Silver May 08 2024 06:55
    82,776.00 -102.00 (-0.12%)
  • Copper May 08 2024 06:55
    853.20 -11.80 (-1.36%)
  • Pound / Rupee Dec 23 2016 22:30
    104.87 +0.26 ( +0.25%)
  • Dollar / Rupee Dec 23 2016 22:30
    83.47 +0.09 ( +0.11%)
  • Euro / Rupee Dec 23 2016 22:30
    89.90 +0.16 ( +0.18%)
  • Yen / Rupee Dec 23 2016 22:30
    0.54 0.00 (-0.42%)

BSE Code : | NSE Symbol : | ISIN:| SECTOR : |

NSE BSE
 

Volume

Prev. Close

Open Price

Bid Price (QTY)

Offer Price (QTY)

 

Today’s High/Low -

52 wk High/Low -

Key Stats

MARKET CAP (RS CR) 40.84
P/E 8.13
BOOK VALUE (RS) 8.9628949
DIV (%) 0.5
MARKET LOT 1
EPS (TTM) 0.93
PRICE/BOOK 0.843477479580844
DIV YIELD.(%) 0.66
FACE VALUE (RS) 10
DELIVERABLES (%)
4

News & Announcements

16-Apr-2024

Family Care Hospitals adjourns board meeting

10-Apr-2024

Family Care Hospitals to conduct board meeting

16-Feb-2024

Family Care Hospitals to conduct board meeting

31-Jan-2024

Family Care Hospitals standalone net profit declines 5.88% in the December 2023 quarter

16-Apr-2024

Family Care Hospitals adjourns board meeting

10-Apr-2024

Family Care Hospitals to conduct board meeting

16-Feb-2024

Family Care Hospitals to conduct board meeting

24-Jan-2024

Family Care Hospitals to conduct board meeting

Corporate Actions

Bonus
Splits
Dividends
Rights
Capital Structure
Book Closure
Board Meeting
AGM
EGM
 

Financials

Income Statement

Standalone
Consolidated
 

Peers Comparsion

Select Company Name BSE Code NSE Symbol
3B Blackbio DX Ltd 532067
Aashka Hospitals Ltd 543346
Aatmaj Healthcare Ltd 78782 AATMAJ
Adeshwar Meditex Ltd 543309
Advanced Micronic Devices Ltd 517552
Amkay Products Ltd 544169
Apollo Hospitals Enterprise Ltd 508869 APOLLOHOSP
Artemis Global Life Sciences Ltd((Merged) 540616 AGLSL
Artemis Medicare Services Ltd 542919 ARTEMISMED
Asarfi Hospital Ltd 543943
Aspira Pathlab & Diagnostics Ltd 540788
Aster DM Healthcare Ltd 540975 ASTERDM
Bandaram Pharma Packtech Ltd 524602
Casil Health Products Ltd(merged) 523254
CDR Health Care Ltd 523353
Centenial Surgical Suture Ltd 531380
Chennai Meenakshi Multispeciality Hospital Ltd 523489
Cure Spects Laser Ltd 531356
Datt Mediproducts Ltd 532171 DATTMEDI
Deccan Hospital Corporation Ltd (Merged) 523258
Dhanvantri Jeevan Rekha Ltd 531043
Digiflex India Ltd 526111
Disposable Medi - Aids Ltd 523540
Dolphin Medical Services Ltd 526504
Dr Agarwals Eye Hospital Ltd 526783
Dr Lal Pathlabs Ltd 539524 LALPATHLAB
Dr Lalchandani Labs Ltd 541299
Emaai Pharma Ltd 524756
Fidelity Industries Ltd (Wound-up) 526425
Fortis Healthcare Ltd 532843 FORTIS
Fortis Malar Hospitals Ltd 523696
Gian Lifecare Ltd 542918
Gil Hospitals Ltd (Wound-up) 526063
Global Health Ltd 543654 MEDANTA
Global Longlife Hospital and Research Ltd 543520
GPT Healthcare Ltd 544131 GPTHEALTH
Healthcare Global Enterprises Ltd 539787 HCG
Hemant Surgical Industries Ltd 543916
Indraprastha Medical Corporation Ltd 532150 INDRAMEDCO
Iswar Medical Services Ltd 507480 ISWARMEDIC
Jupiter Life Line Hospitals Ltd 543980 JLHL
Kemwell International Ltd 530827
Keshlata Cancer Hospital Ltd 40450
Kids Medical Systems Ltd 540812
KK Shah Hospitals Ltd 544013
KMC Speciality Hospitals (India) Ltd 524520
KMS Medisurgi Ltd 540468
Kovai Medical Center & Hospital Ltd 523323 KOVAI
Krishna Institute of Medical Sciences Ltd 543308 KIMS
Krsnaa Diagnostics Ltd 543328 KRSNAA
La Medical Devices Ltd (Wound-up) 524772
Lifeline Injects Ltd 523379
Lokmanya Industries Ltd 526421
Looks Health Services Ltd 534422
Lotus Eye Hospital & Institute Ltd 532998 LOTUSEYE
Maestros Electronics & Telecommun. Systems Ltd 538401
Maestros Mediline Systems Ltd 501209
Maitreya Medicare Ltd 91877 MAITREYA
Max Healthcare Institute Ltd 543220 MAXHEALTH
Medinova Diagnostic Services Ltd 526301
Metropolis Healthcare Ltd 542650 METROPOLIS
Mohini Health & Hygiene Ltd 532585 MHHL
Monozyme India Ltd 522199
N G Industries Ltd 530897
Narayana Hrudayalaya Ltd 539551 NH
New World Medical (India) Ltd 524496
Nidan Laboratories & Healthcare Ltd 535411 NIDAN
Noida Medicare Centre Ltd 523670
Nova Surgikos Ltd 524762
One Global Service Provider Ltd 514330
Opto Circuits (India) Ltd 532391 OPTOCIRCUI
Poly Medicure Ltd 531768 POLYMED
Pramila Kidney Hospitals Ltd 40265
Prevest Denpro Ltd 543363
Rainbow Childrens Medicare Ltd 543524 RAINBOW
Regency Hospital Ltd 526403
Safire Global Medicare Ltd 524418 CDRMEDICAL
Sangam Health Care Products Ltd 531625
Sangani Hospitals Ltd 79231 SANGANI
Secunderabad Healthcare Ltd 524540
Shalby Ltd 540797 SHALBY
Sharma East India Hosp and Medical Research Ltd 524548
Shree Pacetronix Ltd 527005
Siemens Healthcare Diagnostics Ltd(merged) 506559
Soni Medicare Ltd 539378
Sterling (Gujarat) Hospitals Ltd 531741
Surgiplast Ltd 523077
Surlux Diagnostic Ltd 507854
Surlux Health Centres Ltd 523265
Surlux Mediquip Ltd 523515
Tamilnad Hospital Ltd 523443
Tejnaksh Healthcare Ltd 539428
Thyrocare Technologies Ltd 539871 THYROCARE
Transmedica (India) Ltd 526461
Twenty First Century Medicare Ltd 40212
Unihealth Consultancy Ltd 91654 UNIHEALTH
United Diagnostic International Ltd 523485
Vijaya Diagnostic Centre Ltd 543350 VIJAYA
Yatharth Hospital & Trauma Care Services Ltd 543950 YATHARTH

Share Holding

Category No. of shares Percentage
Total Foreign 465915 0.86
Total Institutions 48000 0.09
Total Govt Holding 0 0.00
Total Non Promoter Corporate Holding 883209 1.64
Total Promoters 10013623 18.54
Total Public & others 42604027 78.88
Total 54014774 100
  • Total Foreign
  • Total Institutions
  • Total Govt Holding
  • Total Non Promoter Corporate Holding
  • Total Promoters
  • Total Public & others

About Family Care Hospitals Ltd

Family Care Hospitals Limited was originally incorporated as a Public Limited Company in the name of Pharma Offset Limited. Thereafter, the name of the Company was changed from Pharma Offset Limited to Pharma Com (India) Limited in June, 2000. Again, it was changed from Pharma Com (India) Limited to Count N Denier (India) Limited in March, 2012. Further, it got changed from Count N Denier (India) Limited to Scandent Imaging Limited in June, 2015 and from Scandent Imaging Limited to Family Care Hospitals Limited in June, 2022. Established in 1982 as a partnership firm, Pharma Offset became a public limited company in Sep.'94. It was promoted by Rashmikant C Doshi and Uday M Raval. The Company is presently engaged in Healthcare Services business. The company undertook an expansion-cum-modernisation programme in 1994-95. It came out with a public issue in Jan.'95 to part-finance the project. Pharma Offset supplies its products to reputed pharmaceutical companies like Lyka Labs, Dolphin Laboratories and to multi-nationals like Parke-Davis, Sandoz, Merind, Fulford (India), etc. The company has entered into a firm tie-up with Lyka Labs and Dolphin Laboratories for an offtake of upto 60% of the expanded capacity. In 1998-99, the company commenced an additional activity of trading in chemicals and bulk drugs. During the year 1999-2000, the company has changed its name to Pharma Com (India) Ltd. In 2018, the Company started two hospitals with the name of 'Family Care Hospitals' (FCH) in Mira Road and Mahim. In 2019, it started with their pharmacy business and provided people to buy medicines in a single click in their application specially designed to get them delivered at their convenient location. The FCH family boomed with introducing best multi speciality services viz, cardiology, Neurology, Gastroenterology, Nephrology, Urology, Obstetrics and gynecology, pediatric and neonatology, Orthopedics, General and Laparoscopy surgery. With most qualified and eligible team of doctors, FCH gained patient's trust and delivered high through Patient-Centric approach. FCH provided maximum services with minimum cost which buy belief in patients.

Family Care Hospitals Ltd Chairman Speech

Dear Shareholders,

Your company continued to be invested in the consolidating and growing healthcare services business. Your company during the fiscal has diversified from the core dental diagnostics sector into integrated hospital management services.

Review of FY 2017-18 Performance

Total revenue of your company on rose by 188% in the current year from Rs 179.80 lakhs to Rs 518.84 lakhs.

This growth has largely been a result of your company venturing into the hospital management business. For strategic focus and management purposes, your company initially intends to work in the Western Indian region with a narrower focus on the Mumbai Metropolitan Region in the initial few years of growth. We believe that the Mumbai region itself offers a vast market potential for our services. These are early days of experience for your company and we are in the process of building up the required management and business expertise to deliver sustainable growth in this segment.

Your company's primary business of running the chain of CBCT imaging centres continued to do well.

The number of such centres expanded from 9 centres at the beginning of this fiscal, to 10 centres by end of March 2018. Your company continues to be a leader in the independent third party CBCT imaging centre networks across India. Your company also for the first time, is experimenting the concept of installing OPG imaging machines through our 'OPG Convenience Program' at established Dental clinics belonging to corporate Dental chains, Hospital based Dental clinics & individual owned premium Dental clinics on a revenue sharing formula. During FY2018, a total of 20 OPG machines were installed across Bangalore, Mumbai. Some of the key partners with whom we are providing our OPG services are Axiss Dental South, Ampa Orthodontics, Fortis & Aster Hospitals among others. The results have been so far encouraging and we continue to build on this strength by taking it to other cities in India involving more such clinics. Your company's activities are supported by more than 2500 dentists in Mumbai. These imaging centres are run under the brand name of "Scandent".

Your company took over 3 hospitals in Mumbai. They were an operating 15 bed hospital for management in Saki Naka, a 25 bed hospital in Mahim and a 100 bed infrastructure multi specialty hospital in Mira Road, in Mumbai. These acquisitions were done between August 2017 and March 2018. Totally, the bed capacity available for servicing for your company stands at 140 hospital beds, with interests in medical diagnostics and pharmacy. The aim is to provide secondary level care and support for patients and service all basic needs of the patients in a cost efficient and convenient manner. This is being operated as a separate division within your company and is operated under the brand name "Family Care". We expect every business in this segment to have an initial period of losses, before breaking even in operations as your company would have to make investments into both capex, opex and also ensure on the compliance and management aspects of these businesses. Your company is working on focusing and managing of these risk at all times.

As all these hospitals were either having financial stability issues or limited growth prospects, our team is now focused on turning around every hospital under our management, by adopting centre specific strategies and building on existing business performances. Your company is now fully experiencing the requirements of the hospital business and looks forward to be a meaningful participant in this business. These business expansions are being funded through internal accruals, balances and by borrowings from related group entities.

Consequently, Earnings before Interest, Depreciation and Taxes (EBIDTA) for your company for FY2018 grew by 353% to Rs 159 lakhs from Rs 45 lakhs the previous fiscal. Also, given that our business model is asset light and performance oriented, the net profits for the company grew to Rs 86 lakhs in FY2018 from Rs 16 lakhs in the previous fiscal.

Dividend

As your company has just turned around and does require some more time to mature its businesses and operations, the board of directors has decided to avoid declaring of any dividend for this year.

Business Outlook FY2018-19

Considering that the Indian national elections would be around by the beginning of next year, it would be prudent to avoid expectations of any massive economic growth measures to be unveiled in the last budget for this government. However, as healthcare is a politically sensitive subject, there could be popular measures for public healthcare implemented by the central government which may have a short term negative bias for the private sector business.

The proposed government agenda to give up to Rs 5 lakhs insurance cover per family per year for more than 200 million families with marginal or no incomes can make this significant change to the healthcare business environment. Also, the focus to reduce input costs for stents and other medical equipments could be a positive for our expansion plans in the hospital and diagnostics business. The risks primarily emanate from the ability of our management to deliver on the business turnarounds and the pricing of our acquisitions to ensure an early breakeven.

The recent consolidations and sell outs of some of the larger reputed and larger hospital brands remind us to be very cost effective in our approach and sensitive to the industry ground scenarios. Several of the larger private hospitals and smaller hospital chains are bleeding and/or do not have next generation leaders to lead their businesses. Borrowings have been the key reason for most large companies facing the challenge. For smaller set-ups, it has been their inability to seek and secure the right teams to manage their operations. Our interest in acquiring existing set-ups across a certain region, along with rebranding of the same under "Family Care" and consolidating their operations and increasing our business efficiencies could be our way ahead in this business. We intend to deepen our learning in this business during FY2018. We would be continuing our expansion of the OPG imaging networks this fiscal as well.

Thanking you.

Dr. Gautam Deshpande

Managing Director

DIN:00975368

   

Family Care Hospitals Ltd Company History

Family Care Hospitals Limited was originally incorporated as a Public Limited Company in the name of Pharma Offset Limited. Thereafter, the name of the Company was changed from Pharma Offset Limited to Pharma Com (India) Limited in June, 2000. Again, it was changed from Pharma Com (India) Limited to Count N Denier (India) Limited in March, 2012. Further, it got changed from Count N Denier (India) Limited to Scandent Imaging Limited in June, 2015 and from Scandent Imaging Limited to Family Care Hospitals Limited in June, 2022. Established in 1982 as a partnership firm, Pharma Offset became a public limited company in Sep.'94. It was promoted by Rashmikant C Doshi and Uday M Raval. The Company is presently engaged in Healthcare Services business. The company undertook an expansion-cum-modernisation programme in 1994-95. It came out with a public issue in Jan.'95 to part-finance the project. Pharma Offset supplies its products to reputed pharmaceutical companies like Lyka Labs, Dolphin Laboratories and to multi-nationals like Parke-Davis, Sandoz, Merind, Fulford (India), etc. The company has entered into a firm tie-up with Lyka Labs and Dolphin Laboratories for an offtake of upto 60% of the expanded capacity. In 1998-99, the company commenced an additional activity of trading in chemicals and bulk drugs. During the year 1999-2000, the company has changed its name to Pharma Com (India) Ltd. In 2018, the Company started two hospitals with the name of 'Family Care Hospitals' (FCH) in Mira Road and Mahim. In 2019, it started with their pharmacy business and provided people to buy medicines in a single click in their application specially designed to get them delivered at their convenient location. The FCH family boomed with introducing best multi speciality services viz, cardiology, Neurology, Gastroenterology, Nephrology, Urology, Obstetrics and gynecology, pediatric and neonatology, Orthopedics, General and Laparoscopy surgery. With most qualified and eligible team of doctors, FCH gained patient's trust and delivered high through Patient-Centric approach. FCH provided maximum services with minimum cost which buy belief in patients.

Family Care Hospitals Ltd Directors Reports

Dear Members,

The Board of Directors are pleased to present the 29th Annual Report of the Company along with the Audited Financial Statements for the financial year ended March 31, 2023.

1. FINANCIAL RESULTS AND HIGHLIGHTS:

The Financial performance of the Company for the year ended March 31, 2023 is summarized below:

(Rs. in Lakhs)

Particulars March 31, 2023 March 31, 2022
Revenue from Operations 4,729.69 4206.52
Other Income 98.59 31.33
Total 4828.29 4237.85
Expenditure
Purchase of stock in trade 1,486.99 1449.56
Change in inventory (10.09) 15.08
Employee Benefit Expenses 374.14 371.98
Finance Costs 48.65 42.68
Depreciation 140.94 143.70
Other Expenses 2,045.78 1508.49
Total 4086.40 3531.49
Profit / (Loss) before exceptional and extraordinary items and tax 741.89 706.36
Exceptional items - Discount on Issue of Equity Shares extraordinary items - - - -
Profit / (Loss) from ordinary activities before tax 741.89 706.36
Tax Expense
1. Current Year Tax 192.89 186.48
2. Short provisions for tax of earlier years
3. Deferred tax 23.28
Profit/ (Loss) after Tax 525.72 519.88
Total Other Comprehensive income for the year 1.49 (3.12)
Total Comprehensive income / (loss) for the year 527.22 516.76
Basic EPS 1.64 1.62
Diluted EPS 1.56 1.62

2. INDIAN ACCOUNTING STANDARD:

The Financial Statements for the financial year ended March 31, 2023, forming part of this Annual Report, have been prepared in accordance with Ind AS.

3. COMPANY'S PERFORMANCE:

The Company's total revenue has increased from Rs. 4237.85 in 2021-22 to Rs. 4828.29 lakh in 2022-23 to registering growth of 13.93%. The profit after tax for the year increased to Rs. 525.72 Lakhs as compared to Rs. 519.88 Lakhs in the previous year.

There has been no change in the nature of business of the Company during the year under review. Performance of the Company has also been discussed in detail in the ‘Management Discussion and Analysis Report' forming part of this Annual Report.

4. DIVIDEND:

During the year Company has announced Interim Dividend on 28.11.2022.

5. TRANSFER TO RESERVES:

No amount is proposed to be transferred to the General Reserves of the Company out of the profits for the year.

6. SUBSIDIARY:

During the year under review the Company does not have any Subsidiary Company.

7. CHANGES IN SHARE CAPITAL, IF ANY:

During the year, under Review, Authorised Capital of the Company increase to Rs. 75,00,00,000/- (7,50,00,000 Equity Shares of ? 10/- each) to Rs. 33,50,00,000/- (3,35,00,000 Equity Shares of ? 10/- each)

Company has issued shares by way of Right Issue. Paid capital of the Company increased to Rs. 54,01,47,740/- (5,40,14,774 Equity Shares of ? 10/- each fully paid up from Rs. 32,10,00,000 (3,21,00,000 Equity Shares of ? 10/- each fully paid up)

8. DIRECTORS AND KEY MANAGERIAL PERSONNEL:

During the year under review, all the Independent Directors have furnished Declaration of Independence stating that they meet the criteria of independence as provided under Section 149(6) of the Companies Act, 2013 (‘the Act') and Regulation 16 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘SEBI Listing Regulations') and there has been no change in the circumstances which may affect their status as Independent Directors during the year.

The changes made in the composition of board from the period April 1, 2022 to March 31, 2023:

Sr. No. Name of the Director Designation Date of appointment Date of cessation/expiry of term
1. Mr. Aneish Kumaran Kumar Non Executive Independent Director 16/08/2022
2. Ms. Suryakant Laxman Khare Non Executive Non- Independent Director 20/08/2022
3. Vaishali Sood Sharma Non Executive Independent Director 29/06/2022
4. Rajeev Singh Non Executive Non- Independent Director 29/06/2022
5. Ms. Sapna Kamaldas Vaishnav Company Secretary and Compliance Officer 09/07/2022 14/12/2022

In accordance with the provision of Section 178 and other applicable provisions of the Act and SEBI Listing Regulations, if any, the Nomination and Remuneration Committee has considered and recommended the above appointments/re- appointments to the Board of Directors and Key Managerial Personnel of the Company. A brief resume and other details of all the Directors seeking appointment/ re-appointment are provided in the Notice of AGM.

Pursuant to the provisions of Section 152 of the Act, Mr. Pandoo Naig, Managing Director retires by rotation as Director at the ensuing AGM and being eligible, offers herself for re-appointment. The Board recommends his re-appointment.

In accordance with the provisions of Section 2(51) and 203 of the Act read with the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014,

Name Designation of KMP
Mr. Pandoo Naig Managing Director
Dr. Gautam Deshpande Chief Executive Officer
Mr. Amit Tyagi Chief Financial Officer
Ms. Mohini Waghade Company Secretary (Appointed on 11/08/2023)

9. COMMITTEES OF THE BOARD:

The Company's Board has the following committees;

1. Audit Committee

2. Nomination and Remuneration Committee

3. Stakeholders' Relationship Committee

4. Risk Management Committee

Details of terms of reference of the Committees, Committee membership and attendance at meetings of the Committees are provided in the Corporate Governance report.

10. PUBLIC DEPOSITS:

During the financial year 2022-23, your Company has not accepted any deposit within the meaning of Sections 73 and 74 of the Companies Act, 2013 read together with the Companies (Acceptance of Deposits) Rules, 2014.

11. PARTICULARS OF LOANS, INVESTMENTS AND GUARANTEES UNDER SECTION 186 OF THE COMPANIES ACT, 2013:

The particulars of loans given and investments made during the financial year under Section 186 of the Companies Act, 2013 are given at Notes forming part of the Financial Statements. During the financial year, the Company has neither provided any securities nor provided corporate guarantees for loans availed by the others.

12. SIGNIFICANT AND MATERIAL ORDERS PASSED BY THE REGULATORS OR COURTS:

There are no significant and material orders passed by the Regulators/Courts/Tribunal which would impact the going concern status of the Company and its operations in future.

13. CORPORATE SOCIAL RESPONSIBILITY (CSR):

Corporate Social Responsibility is an integral part of the Company's ethos and policy and it has been pursuing this on a sustained basis. The Company had a Net Profit of more than Rs. 5 crore in the Financial Year 2021-22, hence the provisions of Section 135 of the Companies Act, 2013, at some extent applicable to the Company for the Financial Year 2022-23.

The Company recognizes its obligations to act responsibly, ethically and with integrity in its dealings with employees, community, customers and the environment as a whole, but due to the contingencies in Businesses and unacquaintance of sources of CSR Expenditure, the Company spend Rs. 12,33,180/- (spent after end of financial year but before reporting date of Board Report) out of which Rs. 3,82,921/- is related to the previous year unspent amount. Annexure relating to the same is attached as "Annexure 1".

14. EXTRACT OF ANNUAL RETURN:

As per the provisions of section 92(3) read with section 134(3)(a) of the Act, Annual Return for the Financial Year ended on March 31, 2023, in is available on the website of the Company i.e. www.scandent.in.

15. PARTICULARS OF CONTRACTS OR ARRANGEMENTS MADE WITH RELATED PARTIES:

All related party transactions that were entered into by the Company during the financial year were in ordinary course of business and at arm's length basis. Also, there were related party transactions which could be considered material in accordance with the Policy of the Company on materiality of related party transactions.

All related party transactions are being reviewed and placed before the Audit Committee from time to time for their approval and also been taken on record by the Board.

The information relating to related party transactions is set out in the "Annexure 2" to this Report.

Policy on dealing with related party transactions, is available on the Company's website at http://www.scandent.in/related-party-policy.pdf

16. CORPORATE GOVERNANCE REPORT AND MANAGEMENT DISCUSSION & ANALYSIS REPORT:

A Report on Corporate Governance along with a Certificate from Practicing Company Secretary confirming the compliance of the conditions of Corporate Governance and Management Discussion and Analysis Report forms part of this Annual Report.

17. MATERIAL CHANGES AND COMMITMENTS AFFECTING FINANCIAL POSITION BETWEEN THE END OF THE FINANCIAL YEAR AND DATE OF REPORT:

There are no material changes and commitments between the end of the financial year of the Company and as on the date of this report which can affect the financial position of the Company.

18. NUMBER OF MEETINGS OF THE BOARD:

There were Seven (7) meetings of the Board held during the year. Detailed information is given in the Corporate Governance Report.

19. RETIREMENT BY ROTATION:

Ms. Lucy Massey (DIN 09424796), retires by rotation at the ensuing Annual General Meeting, and being eligible offers herself for re-appointment.

20. DISCLOSURE RELATING TO REMUNERATION OF DIRECTORS. KEY MANAGERIAL PERSONNEL AND PARTICULARS OF EMPLOYEES:

Your Company has been following well laid down policy on appointment and remuneration of Directors, KMP and Senior Management Personnel.

The appointment of Directors is made pursuant to the recommendation of Nomination and Remuneration Committee (‘NRC'). Approval of shareholders for payment of remuneration to Wholetime Directors is sought, from time to time.

The remuneration of Non-Executive Directors comprises of sitting fees in accordance with the provisions of Companies Act, 2013 incurred in connection with attending the Board meetings, Committee meetings, General meetings and in relation to the business of the Company. During the year under review, the Company has not paid any commission to the Non-Executive Directors.

A brief of the Remuneration Policy on appointment and remuneration of Directors, KMP and Senior Management is provided in the Report on Corporate Governance forming part of this Annual Report. Further, the Policy is available on the website of the Company and the web link thereto is http://www.scandent.in/nominationpolicy.pdf

NRC have also formulated criteria for determining qualifications, positive attributes and independence of a director and the same have been provided in the Report on Corporate Governance forming part of this Annual Report.

The information required under Section 197 of the Companies Act, 2013 read with Companies Appointment and Remuneration of Managerial Personnel) Rules, 2014 in respect of Directors/ employees of your Company is set out in "Annexure 3" to this Report.

21. DECLARATION OF INDEPENDENCE:

The Company has received necessary declaration from each Independent Director under section 149 (7) of the Act that he / she meets the criteria of independence laid down in Section 149(6) of the Act and Regulation 16 of SEBI Listing Regulations.

22. BOARD EVALUATION:

One of the key functions of the Board is to monitor and review the Board evaluation framework. The Board of Directors has carried out an annual evaluation of its own performance, Committees and Individual Directors pursuant to provision of the Act and the Corporate Governance requirement as prescribed by SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulation, 2015").

The performance of the Board was evaluated by the board after seeking inputs from all the directors on the basis of the criteria such as the Board composition, structure of the board process, information and functioning, etc.

The Board also carried annual performance evaluation of the working of its Audit, Nomination and Remuneration Committee, Risk Management Committee as well as Stakeholder Relationship Committee. The Board and the Nomination and Remuneration Committee reviewed the performance of the individual Directors.

In a separate meeting of the Independent Director, performance of non -independent Director, performance of Board and performance of the chairman was evaluated, taking in to account the view of Executive Director and Non Executive Director. Performance evaluation of Independent Director was done by the entire Board, excluding the Independent Director being evaluated.

Separate Meeting of the Independent Directors

The Independent Directors held a Meeting on March 29, 2023, without the attendance of Non-Independent Directors and Members of Management. All the Independent Directors were present at such meeting and at the Meeting they have:

i. Reviewed the performance of non-independent directors and the Board as a whole;

ii. Assessed the quality, quantity and timelines of flow of information between the Company Management and the Board that is necessary for the Board to effectively and reasonably perform their duties.

The Present Independent Directors holds a unanimous opinion that the Non- Independent Directors bring to the Board constructive knowledge in their respective field. All the Directors effectively participate and interact in the Meeting. The information flow between the Company's Management and the Board is satisfactory.

Training of Independent Directors

The Company shall provide regular training to independent directors to update them with the regulatory changes and their roles and responsibility in view thereof.

23. STATUTORY AUDITORS AND AUDITOR REPORT:

M/s. S. M. Gupta and Co, Chartered Accountants (Firm Registration No. 310015E), was appointed as Statutory Auditors of your Company at the Annual General Meeting ("AGM") held on 30th November, 2021 for a term of five consecutive years until the conclusion of the Annual General Meeting of the Company to be held for the financial year 2026.

The Board places on record its sincere appreciation for the services rendered by M/s. M. B. Agrawal & Co. during their tenure as Statutory Auditors of the Company. The Board of Directors of the Company at their meeting held on August 13, 2021, based on the recommendation of the Audit Committee, recommended appointment of M/s. S. M. Gupta and Co, Chartered Accountants, (Firm Registration No. 310015E) as the Statutory Auditors of the Company to hold office from the conclusion of this

27th Annual General Meeting till the conclusion of 32nd Annual General Meeting of the Company, subject to compliance of the various provisions of Companies Act, 2013.

M/s. S. M. Gupta and Co. has expressed its willingness to be appointed as the Statutory Auditors of the Company and also confirmed its eligibility in compliance with the provisions of Section 139, 141 and other applicable provisions of the Companies Act, 2013.

Management reply on Statutory Audit Report containing any qualification, reservation or adverse remarks- Auditor's opinion accepted and noted. The Company has not made any provision for the arrear of rent. As the decision of the Court is still awaited and the company is of the view the decision will come in the favour of Company. However the same is provided in the notes to accounts.

24. SECRETARIAL AUDITOR:

Mr. Ajay Kumar of Ajay Kumar & Co., Company Secretaries was appointed to conduct the Secretarial Audit of the Company for the financial year 2022-23, as required under Section 204 of the Companies Act, 2013 and Rule made thereunder. The detailed report on the Secretarial Audit is appended as an "Annexure - 4" to this Report. The comments referred to in the report of the Secretarial auditor are self- explanatory.

25. COST AUDITORS:

Maintenance of cost records and requirement of cost audit as prescribed under the provisions of Section 148 (1) of the Companies Act, 2013 are not applicable to the Company for the FY 2022-23.

26. INTERNAL CONTROL:

The Board ensures the effectiveness of the Company's system of internal controls including financial, operational and compliance control and risk management controls and same is subject to review periodically by the Board of Directors and M/s. Navin Podar & Co,, Chartered accountants, Internal Auditors of the Company for its effectiveness. The control measures adopted by the company have been found to be effective and adequate to the Company's requirement.

27. PREVENTION OF SEXUAL HARASSMENT AT WORKPLACE:

The Company has zero tolerance for sexual harassment at the work place and has adopted a policy on prevention, prohibition and redressal of sexual harassment in line with the provisions of the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013 and the Rules thereunder for prevention and redressal of complaints of sexual harassment at workplace.

Summary of sexual harassment issues raised attended and dispensed during financial year 2023:

• No. of complaints received: 0

• No. of complaints disposed off: 0

• No. of cases pending for more than 90 days: Nil

28. LISTING OF EQUITY SHARES:

Pursuant to the provisions of Listing Agreement with the Stock Exchanges, the Company declares that the Equity Shares of the Company are listed at the BSE Limited.

The Company confirms that it has paid Annual Listing Fees due to BSE Limited up to the Financial Year - 2022-23.

29. DIRECTORS' RESPONSIBILITY STATEMENT:

Pursuant to the requirement under section 134(3) (c) of the Companies Act, 2013, the board of Director, to the best of their knowledge and ability, confirm that:

i. In the preparation of the annual accounts, the applicable accounting standards have been followed along with proper explanation relating to material departures;

ii. They have selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company at the end of the financial year and of the Profit of the Company for year under review;

iii. They have taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of this Act for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;

iv. They have prepared the annual accounts on a going concern basis.

v. They have laid down internal financial controls, which are adequate and are operating efficiently.

vi. They have devised proper systems to ensure compliance with the provisions of all applicable laws and such systems are adequate and operating effectively.

30. SECRETARIAL STANDARDS:

The Company complies with all applicable secretarial standards.

31. RISK MANAGEMENT:

Your Company recognizes that risk is an integral part of business and is committed to managing the risks in a proactive and efficient manner. Your Company periodically assesses risks in the internal and external environment, along with the cost of treating risks and incorporates risk treatment plans in its strategy, business and operational plans.

Your Company, through its risk management process, strives to contain impact and likelihood of the risks within the risk appetite as agreed from time to time with the Board of Directors.

In Line with the regulatory requirement, the Company has constituted a Risk Management Committee to oversee the risk management. The details of the Committee along with its charter are set out in the Corporate Governance Report forming part of this Report. The Risk Management Policy is also posted on the website of the Company.

32. VIGIL MECHANISM/WHISTLE BLOWER:

Your Company is committed to highest standards of ethical, moral and legal business conduct. The Company has adopted a Whistle Blower Policy and has established the necessary vigil mechanism which is in compliance with the provisions of Section 177 (10) of the Companies Act, 2013 and under Regulation 22 of SEBI Listing Regulations 2015, for directors and employees to report concerns about unethical behavior. No person has been denied access to the Chairman of the audit committee. The said policy has been also put up on the website of the Company at the following link: http://www.scandent.in/whistle-blower-policy.pdf

The policy provides for a framework and process whereby concerns can be raised by its employees against any kind of discrimination, harassment, victimization or any other unfair practice being adopted against them.

33. CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION & FOREIGN EXCHANGE EARNING & OUTGOINGS:

The particulars as prescribed under sub- section (3) (m) of Section 134 of the Companies Act, 2013, read with Companies (Accounts) Rules, 2014 are hereunder:

a) conservation of energy

(i) the steps taken or impact on conservation of energy NIL
(ii) the steps taken by the company for utilizing alternate sources of energy NIL
(iii) the capital investment on energy conservation equipment's NIL

(b) Technology absorption

(i) the efforts made towards technology absorption NIL
(ii) the benefits derived like product improvement, cost reduction, product development or import substitution NIL
(iii) in case of imported technology (imported during the last three years reckoned from the beginning of the financial year)-
(a) the details of technology imported NIL
(b) the year of import; NIL
(c) whether the technology been fully absorbed NIL
(d) if not fully absorbed, areas where absorption has not taken place, and the reasons thereof NIL
(iv) the expenditure incurred on Research and Development NIL

(c) Foreign Exchange earning & outgoings

For Year Ended 31st March 2023 (Rupees) For Year Ended 31st March 2022 (Rupees)
Expenditure-
Foreign Travel NIL NIL
Freight Forwarding Expenses NIL NIL
Income- Commission and other income NIL NIL

34. FRAUDS:

During the year under review, neither the statutory auditors nor the secretarial auditor has reported to the audit committee, under section 143(12) of the Act, any instances of fraud committed against the Company by its officers or employees, the details of which would need to be mentioned in the Directors' Report.

35. CAUTIONARY STATEMENT:

Certain statements in the Directors' Report describing the Company's objectives, projections, estimates, expectations or predictions may be forward-looking statements within the meaning of applicable securities laws and regulations. Actual results could differ from those expressed or implied. Important factors that could make a difference to the Company's operations include labour and material availability, and prices, cyclical demand and pricing in the Company's principal markets, changes in government regulations, tax regimes, economic.

36. ACKNOWLEDGEMENTS:

The Board expresses its gratitude and appreciates the assistance and co-operation received from the Banks, Government Authorities, Customers, Shareholders and other Stakeholders during the year under review.

For and on behalf of the Board of Directors
Family Care Hospitals Limited
Sd/- Sd/-
Pandoo Naig Lucy Massey
Managing Director Director
DIN: 00158221 DIN:09424796

   

Family Care Hospitals Ltd Company Background

Pandoo Neig
Incorporation Year1994
Registered OfficePlot No A-357 Road No 26,Wagle Industrial Estate MIDC
Thane (West),Maharashtra-400604
Telephone91-22-25833205,Managing Director
Fax91-22-25833205
Company SecretaryMohini Waghade
AuditorS M Gupta & Co/M B Agrawal & Co
Face Value10
Market Lot1
ListingBSE,
RegistrarPurva Sharegistry (I) Pvt Ltd
9 ShivShakti Indl Es,J R Boricha Marg,Lower Parel,Mumbai - 400 011

Family Care Hospitals Ltd Company Management

Director NameDirector DesignationYear
Rajnish Kumar PandeyIndependent Director2022
Pandoo NeigManaging Director2022
Dhananjay ParikhNon-Exec. & Independent Dir.2022
Lucy MasseyAddtnl Non-Executive Director2022
Mohini WaghadeCompany Sec. & Compli. Officer2022

Family Care Hospitals Ltd Listing Information

Family Care Hospitals Ltd Finished Product

Product NameUnit Installed
Capacity
Production
Quantity
Sales
Quantity
Sales
Value
Sale of ServicesNA00014.18925
Sales taxNA0000
Bulk Drugs & Chemicals-TradedKg0000
Printed Cartons& Catch-coversNo0000
DiariesNo0000
Printed LablesNo0000
Printed Direction SheetsNo0000
Booklets & Medical FolderNo0000
MachinesNo0000
Excise DutyNA0000
Packing Charges (Collection)NA0000

Contact us Contact us